Arm 2, P = 0.037) and in HCV genotype 3-infected patients (Cohort 3 vs. Cohort 6, P = 0.037) ( Table 3). SVR12 http://www.selleckchem.com/products/pifithrin-alpha.html was achieved by 10 (100%; 95% CI 69–100) HCV genotype 1-infected patients, 8 (80%; 95% CI, 44–97) HCV genotype 2-infected patients, and 5 (50%; 95% CI, 19–81) HCV genotype 3-infected patients

receiving the RBV-containing regimen. All of these patients went on to achieve SVR24, except for 1 HCV genotype 3-infected patient who relapsed at post-treatment week 24. Phylogenetic analysis indicates that this was likely a new infection with HCV subgenotype 2b. The resulting SVR24 rate was 40% (95% CI, 12–74) in HCV genotype 3-infected patients receiving the RBV-containing regimen. SVR12 was achieved by 6 (60%; 95% CI, 26–88) HCV genotype 1-infected patients, 6 (60%; 95% CI, 26–88) HCV genotype 2-infected patients, and 1 (9%; 95% CI, 0–41) HCV genotype 3-infected patient receiving the RBV-free regimen. All of these patients achieved SVR24. SVR12 rates were greater with the RBV-containing regimen compared to the RBV-free regimen overall (Arm 1 vs. Arm 2, P = 0.005), in HCV genotype 1-infected patients (Cohort 1 vs. Cohort 4, P = 0.037), and in HCV genotype 3-infected patients (Cohort 3 vs. Cohort 6, P = 0.046) ( Table 3). SVR24 rates with the RBV-containing regimen compared to the RBV-free regimen were greater overall (Arm 1 vs. Arm 2, P = 0.008)

and in HCV learn more genotype 1-infected patients (Cohort 1 vs. Cohort 4, P = 0.037). Among patients receiving the RBV-containing regimen, no HCV genotype PF-02341066 price 1-infected patient experienced virologic failure, 1 HCV genotype 2-infected patient experienced breakthrough, and there were 3 breakthroughs

and 2 relapses in HCV genotype 3-infected patients. Among patients receiving the RBV-free regimen, there was 1 breakthrough and 2 relapses in a genotype 1-infected patient, and 1 breakthrough and 2 relapses in genotype 2-infected patients; there were 8 breakthroughs and 1 relapse in genotype 3-infected patients. All three HCV genotype 1-infected patients experiencing virologic failure had subgenotype 1a. All four HCV genotype 2-infected patients experiencing virologic failure had subgenotype 2b. Two patients who relapsed (1 HCV genotype 2-infected patient and 1 HCV genotype 3-infected patient receiving the RBV-free regimen) took less than 40% of their prescribed doses of each study drug. Of the 4 patients with baseline resistance-associated variants in NS5A, 1 subgenotype 1a-infected patient and 1 subgenotype 2a-infected patient achieved SVR12 and SVR24, 1 subgenotype 1a-infected patient experienced breakthrough, and 1 subgenotype 1a-infected patient relapsed. Two subgenotype 3a-infected patients had baseline resistance-associated variants in NS3 protease; both experienced breakthrough.